Intracellular kinases play a ubiquitous role in signaling pathways within cells. Receptor tyrosine kinases function at the beginning of a number of signal transduction cascades, whereas ...

2014年12月， 复旦大学附属肿瘤医院 在Oncotarget期刊上发表了一篇论文。在 发表4年后 ，因 图片组内重复 在pubpeer上被读者质疑。 论文题为 “Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor ...

Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical ...

Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

DelveInsight’s c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline ...

Dr. Jonathan R. Strosberg, discussed results of the CABINET trial evaluating Cabometyx versus placebo in advanced ...

Results have been announced from a Phase III trial of Merck & Co’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima ...

Equities researchers at StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) in a report released on Thursday. The firm set a “hold” rating on the stock ...

Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic ...

Inhibikase Therapeutics, Inc.’s IKT share price has dipped by 31.43%, which has investors questioning if this is right time ...

MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...